Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd cut its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 16.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,326 shares of the pharmaceutical company’s stock after selling 653 shares during the period. Harvest Fund Management Co. Ltd’s holdings in Vertex Pharmaceuticals were worth $1,334,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in VRTX. Venturi Wealth Management LLC boosted its position in shares of Vertex Pharmaceuticals by 1.1% during the 4th quarter. Venturi Wealth Management LLC now owns 2,293 shares of the pharmaceutical company’s stock worth $933,000 after acquiring an additional 24 shares in the last quarter. Nicholas Hoffman & Company LLC. boosted its position in shares of Vertex Pharmaceuticals by 3.9% during the 4th quarter. Nicholas Hoffman & Company LLC. now owns 636 shares of the pharmaceutical company’s stock worth $259,000 after acquiring an additional 24 shares in the last quarter. Arthur M. Cohen & Associates LLC boosted its position in shares of Vertex Pharmaceuticals by 3.2% during the 4th quarter. Arthur M. Cohen & Associates LLC now owns 800 shares of the pharmaceutical company’s stock worth $326,000 after acquiring an additional 25 shares in the last quarter. Baystate Wealth Management LLC boosted its position in shares of Vertex Pharmaceuticals by 49.0% in the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after purchasing an additional 25 shares during the period. Finally, Arjuna Capital boosted its position in shares of Vertex Pharmaceuticals by 0.7% in the 3rd quarter. Arjuna Capital now owns 4,375 shares of the pharmaceutical company’s stock valued at $1,521,000 after purchasing an additional 29 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the sale, the executive vice president now owns 74,364 shares in the company, valued at approximately $31,250,727.36. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the sale, the executive vice president now owns 74,364 shares in the company, valued at approximately $31,250,727.36. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Ourania Tatsis sold 354 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the sale, the executive vice president now owns 55,804 shares in the company, valued at approximately $23,755,762.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,381 shares of company stock worth $5,203,249. 0.20% of the stock is owned by insiders.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX traded up $4.99 during mid-day trading on Tuesday, hitting $404.91. The stock had a trading volume of 1,070,081 shares, compared to its average volume of 1,246,031. Vertex Pharmaceuticals Incorporated has a 52-week low of $316.43 and a 52-week high of $448.40. The company has a market cap of $104.65 billion, a price-to-earnings ratio of 29.15, a P/E/G ratio of 1.86 and a beta of 0.35. The company has a 50 day simple moving average of $413.00 and a 200 day simple moving average of $398.36. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, beating the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The firm had revenue of $2.52 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same period last year, the business posted $3.33 EPS. Equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Canaccord Genuity Group reissued a “sell” rating and issued a $371.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, April 12th. HC Wainwright upped their target price on Vertex Pharmaceuticals from $457.00 to $462.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Maxim Group cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Barclays upped their target price on Vertex Pharmaceuticals from $446.00 to $472.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Finally, JPMorgan Chase & Co. upped their target price on Vertex Pharmaceuticals from $390.00 to $438.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $429.45.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.